Nitric oxide in primary ciliary dyskinesia

Woolf T. Walker, Claire L. Jackson, Peter M. Lackie, Claire Hogg, Jane S. Lucas


Nitric oxide is continually synthesised in the respiratory epithelium and is upregulated in response to infection or inflammation. Primary ciliary dyskinesia (PCD) is characterised by recurrent sinopulmonary infections due to impaired mucociliary clearance. Despite chronic infections, nasal nitric oxide in such patients is markedly reduced and is used as a screening test for this condition. These low levels were first described >15 yrs ago but the underlying mechanisms have yet to be fully elucidated. We review epithelial nitric oxide synthesis, release and measurement in the upper airways with particular reference to PCD. The key hypotheses that have been proposed to explain the low nitric oxide levels in this condition are explored and the potential benefits of augmenting airway nitric oxide levels are considered. Further work in these patients clarifying both whether the respiratory epithelium is able to biosynthesise normal levels of nitric oxide and the role played by abnormalities in the anatomy of the paranasal sinuses is essential. While nitric oxide augmentation is unlikely to be beneficial in common PCD phenotypes, it has potential in the treatment of secondary dyskinesias and may also improve treatment of bacterial infections, particularly where biofilms are implicated.

Primary ciliary dyskinesia (PCD) is a rare autosomal recessive disorder, with considerable heterogenicity, characterised by a spectrum of corresponding defects in ciliary ultrastructure and/or ciliary function [1]. The impaired ciliary function impedes mucociliary clearance, which predisposes the patient to recurrent sinopulmonary infection [2]. Nitric oxide is a highly reactive gaseous molecule with numerous signalling roles within the airways. It is produced throughout the airways but is particularly abundant in the nasal sinuses [3]. Nitric oxide biosynthesis is typically upregulated during infection, via increased inducible nitric oxide synthase (iNOS) transcription and activity [4]. Despite recurrent respiratory infection, nasal concentrations of nitric oxide are markedly reduced in the vast majority of PCD patients, compared with those without the disorder. Indeed, nasal NO is now widely used as a screening test for PCD [5, 6]. Exhaled nitric oxide fraction (FeNO) from the lower airway is also low in PCD but is less specific at differentiating between PCD and healthy controls [3, 7, 8]. While the association between low nasal nitric oxide and PCD has been recognised for >15 yrs, the underlying mechanisms causing this phenomenon remain unclear.

Here, we review studies of nitric oxide in the airway, focusing on epithelial-derived nitric oxide and the low levels found in PCD patients. We explore key hypotheses proposed to explain the lower nitric oxide and consider whether augmentation of nitric oxide would benefit these patients.


Nitric oxide is an intra- and intercellular signalling molecule involved in diverse physiological and pathophysiological processes [9], such as vascular homeostasis, immune cell activity and tumour progression [10]. Nitric oxide has a short half-life and diffuses rapidly from its point of synthesis, interacting intracellularly as well as crossing the plasma membrane and leaving the cell, where it can act extracellularly [11, 12]. Nitric oxide is synthesised via the oxidation of the amino acid l-arginine to l-citrulline, catalysed by three stereospecific isoenzymes in the presence of nicotinamide adenine dinucleotide phosphate, oxygen and other cofactors (fig. 1). The isoenzymes neuronal nitric oxide synthase (nNOS) and endothelial NOS (eNOS) are expressed constitutively and require calmodulin binding and calcium activity to produce femtomole or picomole concentrations of nitric oxide [13]. In contrast, iNOS is permanently bound to calmodulin and is therefore independent of calcium activity. It may be transcriptionally induced by a number of cytokines, including interleukin-1β, tumour necrosis factor-α and interferon-γ [14], to produce nanomole concentrations of nitric oxide [4, 13]. The expression of iNOS may also be constitutive in airway epithelium [14]. NOS isoenzyme gene expression and protein localisation have been demonstrated in the airway (table 1).

Figure 1–

Schematic diagram to demonstrate nitric oxide biosynthesis by the conversion of l-arginine (nitric oxide synthase (NOS) substrate) to l-citrulline via NOS isoenzymes. During this process, the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), is oxidised in the presence of oxygen to form nicotinamide adenine dinucleotide phosphate (NADP+) and water. Other cofactors are also required for nitric oxide biosynthesis (not shown).

View this table:
Table 1– Expression and protein localisation in the human airway of the nitric oxide synthase (NOS) isoenzymes

Within the airway, nitric oxide is produced by numerous cell types, including epithelial cells, endothelial cells, fibroblasts, activated macrophages, nerve cells, and airway and vascular smooth muscle cells. It has diverse roles as a modulator of ciliary function, neurotransmission, bronchodilatation, vasodilatation, platelet aggregation and immune function [13]. With regard to ciliary function, in vitro studies of animal and human airway ciliated epithelium suggest that the induction of NOS and nitric oxide production increase ciliary beat frequency [2026]. During oxidative stress conditions, the production of nitric oxide and reactive nitrogen species amplify inflammatory responses and, hence, may modulate chronic airway inflammatory disease [13]. Additionally, the production of nitric oxide within the airway is protective against infection, and has bacteriostatic and bactericidal activity; sodium nitrite can kill Pseudomonas aeruginosa, Staphylococcus aureus and Burkholderia cepacia [27]. It can also modulate biofilm formation [28], and cause biofilm dispersal, making the bacteria more susceptible to antimicrobial treatment [29].


PCD is a heterogeneous disorder, usually inherited as an autosomal recessive trait [6], causing a range of ciliary ultrastructural and functional defects, and resultant ciliary dyskinesia [30]. The prevalence of PCD is estimated to be 1 in 15,000–30,000 live births [6, 31, 32]. PCD is characterised by chronic upper and lower airway infection, and is associated with situs inversus and male infertility due to homology between respiratory cilia, embryonic nodal cilia and sperm.

The motile ciliary axoneme is formed in a “9+2” arrangement where nine peripheral microtubule doublets surround a central pair of single microtubules [33]. Over 250 other proteins maintain this structure, including radial spokes and nexin links. The inner and outer arms of the axoneme generate the force required for ciliary beating and are formed by dynein complexes, acting as mechanochemical ATPases [34]. Radial spokes structurally coordinate the ciliary beat pattern (CBP); hence, mutations affecting dynein arms or radial spokes render ciliary movement ineffective and dyskinetic [35]. Development of a genetic diagnosis for PCD has remained problematic due to the heterogenicity of the disease and, in some cases, candidate genes having large exomes. To date, there are 11 published PCD-causing gene mutations, which account for approximately one-third of PCD cases [36, 37], and genetic diagnostic techniques are being developed [6, 36].


Diagnosis of PCD can be confirmed by analysis of ciliated bronchial or nasal epithelia. There is no “gold standard” test that will diagnose all PCD phenotypes, and hence a diagnostic workup requires the rigorous assessment of CBF and ciliary beat pattern (CBP) by high-resolution, high-speed video microscopy and transmission electron microscopy of ciliary ultrastructure, as recommended by the European Respiratory Society Task Force consensus statement [6]. Assessment of CBP requires a high degree of experience and skill, but considering CBF in isolation risks misdiagnosing PCD. There is also an increasing literature on a population of atypical patients with PCD and normal ciliary ultrastructure, associated with mutations in dynein axonemal heavy chain [11], that would be missed in centres where diagnosis depends on electron microscopy without access to high-speed video microscopy [3840]. For difficult diagnostic cases, the re-differentiation of basal epithelial cells at an air–liquid interface in cell culture allows for reassessment of ciliary function and ultrastructure that may differentiate primary from secondary dyskinesia [6, 41, 42].


Only a small percentage of patients presenting with chronic upper and lower respiratory tract infections have PCD. Diagnostic investigation of PCD, outlined above, requires specialist skills, and is time consuming, costly and only available in a small number of specialist centres. A reliable screening test is therefore desirable [41]. For many years, the saccharin test was used, but it is difficult to perform and is unreliable in children [6, 43].

Nitric oxide detection in human exhaled breath was first described in 1991 [44]. Studies suggest that the majority of nitric oxide originates from the paranasal sinuses, with lower concentrations found in exhaled breath [18, 45]. Paranasal sinus biopsies taken from healthy controls demonstrated that iNOS isoenzyme expression was most abundant in in situ hybridisation and immunohistochemistry experiments, and notably more so than seen in matched nasal biopsies, suggesting iNOS as the predominant isoenzyme involved in nitric oxide biosynthesis within the paranasal sinuses [18, 46].

PCD patients have low nasal nitric oxide and FeNO compared with healthy controls (table 2) [3, 7, 8]. Nasal nitric oxide is sufficiently low in PCD to be used as a screening test for the condition [3, 7, 47, 48, 52, 54]. One group reported a specificity of 88%, a sensitivity of 100% and a positive predictive value of 89% for correctly diagnosing PCD when using a nasal nitric oxide cut-off level of <105 ppb [48]. While initially undertaken as a research tool, nasal nitric oxide was quickly introduced as part of the clinical diagnostic pathway in many larger European PCD centres. It has been included in the British guidelines since 2007 [5] and European consensus guidelines since 2009 [6]. Nasal nitric oxide measurement is not yet approved for clinical use in the USA where only centres with major research programmes in PCD are routinely using it. The measurement is extremely helpful in guiding the diagnostic pathway, but major drawbacks are the cost of equipment and consumables. It is also important to note that there is no widely agreed cut-off level used for the screening of PCD as levels vary significantly with age, due to the development of the paranasal sinuses over the first decade of life, and, to a lesser extent, with the device used to perform the measurement [18, 55]. Nasal nitric oxide has also been found to be useful in atypical phenotypes where normal ciliary ultrastructure makes diagnosis difficult [38, 54]. While the best validated technique for the measurement of nasal nitric oxide is performed by nasal aspiration during breath holding [56], there is recent literature on levels recorded in PCD patients during both humming and tidal breathing. Tidal measurements allow levels to be measured in children as young as 6 months of age, although there is limited experience in this age younger age group [55, 57].

View this table:
Table 2– Main studies assessing exhaled nitric oxide fraction and nasal nitric oxide in patients with primary ciliary dyskinesia (PCD) compared to healthy controls

Contrary to the majority of published data [3, 7, 47, 48, 52, 54], two groups [53, 58] have recently reported normal and raised levels of nasal nitric oxide in patients with PCD. A study of PCD-positive patients, confirmed by live ciliary function analysis and scrutiny of ciliary axonemal ultrastructure [6], reported five patients with nasal nitric oxide within or above the normal range [53]. A further study demonstrated that 24% of patients at an Italian PCD clinic (n=41) had nasal nitric oxide of >250 ppb, although the diagnostic evidence for PCD in these patients is unclear [58]. These studies highlight that patients with a history strongly suggestive of PCD should not be excluded from further diagnostic evaluation on the basis of nasal nitric oxide.

The value of using nasal nitric oxide as a screening tool for PCD is clear, but there are a number of other conditions in which reduced nasal nitric oxide levels occur, although usually not as low as in PCD, including cystic fibrosis [59], diffuse panbronchiolitis [60], nasal polyps [61] and chronic sinusitis [62]. It is also reduced in smokers [63]. The lack of specificity requires robust diagnostic evaluation to confirm PCD in patients with low nasal nitric oxide.


Exhaled lower airway nitric oxide as measured by FeNO is typically sampled at a set exhalation flow rate of 50 mL·s−1, denoted as FeNO50[56]. Several two-compartment mathematical models have been described, allowing estimates of alveolar nitric oxide (Calv,NO) and conducting airway nitric oxide (Jaw,NO) [64, 65]. The two-compartment model has been used to investigate whether low nitric oxide is confined to the upper airway in PCD, or whether it is low throughout upper and lower airways. Three published studies that have used the multiple-flow technique to estimate Jaw,NO and Calv,NO in PCD patients have conflicting findings [49, 51, 66]. All found Jaw,NO was reduced in PCD compared with controls but only one [66] found low Calv,NO. While further work is needed to consider this discrepancy, the model might suggest that the lower FeNO50 seen in PCD compared to controls is principally due to a decreased bronchial biosynthesis of nitric oxide.


Several hypotheses have been put forward at both a cellular and anatomical level for the low airway nitric oxide in PCD; some extrapolated from the finding of reduced nitric oxide levels seen in cystic fibrosis [6770]. At the epithelial level, it has been suggested that there is reduced biosynthesis of NO [8, 50, 69] or increased breakdown, either within the cell, in a viscous mucus layer [67, 68] or by denitrifying bacteria [50]. At the anatomical level, it has been suggested that nitric oxide is sequestered in the upper respiratory tract within blocked paranasal sinuses or, alternatively, nasal nitric oxide biosynthesis or nitric oxide storage capacity is limited due to agenesis of the sinuses (fig. 2) [58, 71].

Figure 2–

Schematic diagram to represent normal nitric oxide metabolism and release from the epithelium of healthy subjects, and hypotheses for the potential causes of low nasal nitric oxide concentrations in primary ciliary dyskinesia (PCD), based on events at the epithelium. A: increased breakdown of highly reactive nitric oxide to nitric oxide metabolites (nitrite and nitrates), either within the epithelial cell, within extra viscous sputum or by denitrifying bacteria within the mucus; hence, nitric oxide metabolites are predominantly released into the airway (hypothesis 1). B: absence of, or reduced, nitric oxide biosynthesis within the epithelial cell (hypothesis 2). C: normal nitric oxide biosynthesis within the epithelial cell; however, obstruction to the osteomeatal complex inhibits nitric oxide release from the paranasal sinuses into the nasal passage (hypothesis 3). Alternatively, hypoplasia or agenesis of the paranasal sinuses reduces nitric oxide production and storage capacity; hence, low measurable nasal nitric oxide levels are seen (hypothesis 4).

We review below four broad hypotheses that have been proposed to explain the low nitric oxide levels found in patients with PCD.


As nitric oxide is highly reactive, it is rapidly broken down from the breath exhalate by its reaction with, among others, oxygen, superoxides and cysteine thiols, producing reactive nitrogen species, including the potent oxidants peroxynitrite and nitrogen dioxide, and S-nitrosothiols [7275].

The low nitric oxide levels seen in PCD may be associated with increased consumption of nitric oxide by superoxide anions to form reactive nitrogen species, which has been suggested as the cause of low nitric oxide in adult respiratory distress syndrome [76]. A study of 23 PCD patients and 11 healthy volunteers seemed to support this, demonstrating increased concentrations of the oxidative stress marker 8-isoprostane (8-IP) in the PCD group. However, there were a number of PCD patients with apparently normal 8-IP levels, which is inconsistent with oxidative stress associated rapid breakdown of nitric oxide in these patients [77]. Csoma et al. [50] demonstrated no difference in the mean concentrations of three nitric oxide metabolites (nitrite, nitrite/nitrate or S-nitrosothiol) in the exhaled breath condensates of 15 PCD patients with markedly decreased nasal nitric oxide levels (table 2), compared with 14 healthy controls, suggesting that nitric oxide biosynthesis does occur in the PCD airway. Given the variability in levels of oxidative stress seen in PCD patients, it seems unlikely that this alone is responsible for the consistently low nitric oxide detection in PCD; however, further experimental work is required.

Nitric oxide is trapped and broken down in viscous sputum

Impaired mucociliary clearance in PCD causes mucus accumulation in the airways, potentially trapping nitric oxide at the periciliary level or in the mucus itself, where it is then broken down into nitric oxide metabolites. In cystic fibrosis patients, it has been suggested that the viscous mucus may trap the highly reactive nitric oxide, preventing it from being exhaled freely [67, 68]. Viscous mucus is a particular issue for cystic fibrosis patients but similar biophysical properties have been identified in sputum of patients with PCD [78]. The significance of this potential mechanism requires further evaluation.

Consumption of nitric oxide by denitrifying bacteria

Increased breakdown of airway nitric oxide by bacterial nitric oxide reductase may contribute to low FeNO [79]. There is evidence in cystic fibrosis that chronic colonisation of the airway with denitrifying organisms lowers FeNO and that antibiotic treatment for exacerbations increases nitric oxide concentrations [70]. PCD patients similarly suffer from recurrent infection and, to some degree, colonisation, but to our knowledge, the effect of antibiotic treatment on FeNO has not been assessed. However, denitrifying bacteria seem unlikely to be the cause of the low nitric oxide concentrations seen as cystic fibrosis patients are more chronically colonised with bacteria than patients with PCD but have significantly higher nasal nitric oxide concentrations.


Nitric oxide synthesis occurs in patients with PCD [50]; however, a number of reasons why synthesis may be reduced in PCD epithelia have been postulated. These include an absence or decreased expression of NOS isoenzymes, a reduction in NOS isoenzyme output directly related to loss of ciliary function [8] or limitations in the availability of the NOS substrate l-arginine, either due to its reduced availability or increased metabolism [69, 8082].

Decreased expression of NOS isoenzymes

It has been suggested that iNOS is the main contributor to FeNO, when looking at healthy, asthmatic and atopic children [83]. It has also been reported that patients with cystic fibrosis have reduced or absent iNOS expression in the airway epithelia [79, 84, 85]. A recent study comparing NOS2 and NOS3 mRNA expression (the genes for iNOS and eNOS, respectively) in the nasal mucosa of patients with PCD and secondary ciliary dyskinesia (SCD) found that there was no difference in NOS3 expression but lower levels of NOS2 expression in the PCD group. There was, however, significant overlap between the two groups, making these results difficult to interpret. [82]. Since PCD is a polygenic disorder, its genetic linkage to NOS gene polymorphisms is highly unlikely. Furthermore, “next-generation sequencing” of exomes, targeted to identify PCD causing genetic mutations, to date, has not identified the NOS genes (NOS1, NOS2 and NOS3) as candidate genes for PCD [36].

Loss of NOS activity via mechanochemical uncoupling in PCD

Narang et al. [8] proposed that normal NOS activity requires ciliary function via a mechanochemical coupling to dynein ATPases, which would be uncoupled in patients with PCD. This hypothesis was based on observations from patients with Duchenne muscular dystrophy (DMD) where mutations in the dystrophin gene result in an uncoupling of nNOS from the contractile apparatus, leading to the loss of contractile function seen in DMD, causing low serum nitric oxide [8688]. While further work is required to elucidate the mechanism regulating NOS activity, an uncoupling of NOS from dynein ATPase seems unlikely as PCD phenotypes with hyper-frequent or motile dyskinetic cilia have low nitric oxide similar to patients with static cilia.

Limitations to availability of the NOS substrate l-arginine

Arginase competes with NOS isoenzymes for their common substrate l-arginine. It has been suggested in cystic fibrosis that high levels of arginase may be present and compete with NOS isoenzymes for l-arginine, hence leading to reduced nitric oxide biosynthesis [69]. In cystic fibrosis, high levels of arginase activity are seen in sputum even after 14 days of intravenous antibiotics, which significantly lowers arginase activity when compared with induced sputum from healthy control subjects (p=0.0001) [69]. While this has not been directly assessed in PCD patients, there have been pilot studies that demonstrate increased nasal and exhaled nitric oxide levels in PCD patients following administration of both intravenous and nebulised l-arginine, as discussed further below [82, 89]. Further work is needed to clarify the availability of this NOS substrate in PCD epithelial cells.


In health, the predominant source of exhaled nitric oxide is the upper airway [45]. Evidence from studies using manoeuvres such as humming suggest nitric oxide is sequestered within the nasal cavities [71, 90, 91]. The oscillation generated by the humming is thought to increase gas exchange across the osteomeatal complex [90, 92]. During tidal breathing, it can take up to 30 min to completely clear sinus gases into the nasal cavity, but with humming, this occurs in one exhalation [93, 94]. In healthy volunteers, humming leads to a 15-fold peak in nasal nitric oxide, compared with quiet exhalation [90]. This humming peak is absent in patients with chronic sinusitis and those with cystic fibrosis [91, 95]. There is evidence, in both these conditions, to suggest this is secondary to decreased expression of iNOS, leading to decreased nitric oxide biosynthesis [79, 84, 85, 96]. Patients with PCD suffer from chronic sinusitis and, in a small study, the absence of a nasal nitric oxide humming peak has been demonstrated in PCD compared with healthy controls [71]. In this study, 13 of the 14 PCD patients underwent a computed tomography scan of the paranasal sinuses and no differences were seen in nasal nitric oxide humming peaks between those who had complete opacification of the paranasal sinuses and those with only partial opacification with patent osteomeatal complexes; however, the numbers were small [71].

A recent observational study reported five patients with PCD with normal nasal nitric oxide levels [53]. Notably, none of these five patients suffered from chronic sinusitis [53], supporting the hypothesis that a patent osteomeatal complex permits normal nasal nitric oxide levels in PCD. However, in the authors’ patient population, some had PCD without sinusitis but very low nasal nitric oxide and there are very few reported cases of PCD patients with normal nasal nitric oxide levels, raising the possibility that these five patients may have an unusual phenotype or have been incorrectly diagnosed with PCD.

So, while it has been demonstrated that humming does not increase nasal nitric oxide in PCD patients, it remains unclear whether this is a consequence of the underlying inability of the airway epithelia to produce nitric oxide or that the manoeuvres did not overcome the obstruction to the osteomeatal complex.


Aplastic or hypoplastic nasal sinuses can occur in PCD and would lead to both absent or reduced epithelial production and storage capacity of NO in the paranasal sinus, respectively. This might explain, particularly given the importance of the paranasal sinuses in nitric oxide production [45], why nasal nitric oxide concentrations are low and do not vary significantly with manoeuvres that improve sinus ventilation [58, 71, 97]. In a recent study, computed tomography scans of the paranasal sinuses at the time of diagnostic investigation for PCD demonstrated that frontal and/or sphenoidal sinuses were either aplastic or hypoplastic in 30 (73%) out of 41 PCD patients, compared to only 38% of those with SCD [58]. There was a significant inverse correlation between the score for aplasia/hypoplasia of each paranasal sinus and nasal nitric oxide values in PCD (r= -0.432, p=0.008) but not in SCD (r= -0.271, p=0.07) [58], supporting the hypothesis that smaller sinuses are associated with lower nasal nitric oxide levels. However, unusually, 24% of this PCD study population had normal nasal nitric oxide; if these patients were excluded, no correlation between aplasia/hypoplasia score and nasal nitric oxide level would have been seen. There is again the possibility that these “outliers” with normal nitric oxide may have an unusual PCD phenotype or have been incorrectly diagnosed.

Further evidence in support of this hypothesis is that the paranasal sinuses develop over the first 10 yrs of life and nasal nitric oxide levels are seen to increase with age over this time period [18]. It is also noteworthy that most conditions associated with lower nasal nitric oxide levels involve disease of the paranasal sinuses, cystic fibrosis [59, 98], nasal polyps [61], chronic sinusitis [62] and PCD, which may lead to either obstruction of the osteomeatal complex or reduced storage capacity of the paranasal sinuses, or a combination of both.


As the evidence that nitric oxide plays a functional role in the lung increases, research has focused on augmenting levels to observe effects. Most of the work in this field has been undertaken using the NOS substrate l-arginine, which increases FeNO levels in healthy subjects [81, 82, 99, 100].

Nasal nitric oxide and FeNO levels have been compared before and after infusion of intravenous l-arginine in PCD (n=7) and healthy controls (n=11). A 1.4-fold increase in nasal nitric oxide occurred immediately after infusion and a 1.8-fold increase in FeNO 3 h after infusion in PCD patients. However concentrations remained reduced compared with the baseline values of the control group [82]. Another group compared the use of nebulised l-arginine in 10 PCD patients with 10 healthy controls in a double-blinded, placebo-controlled trial. They found that l-arginine not only increased nasal nitric oxide levels but also increased CBF and decreased mucociliary clearance time [89]. However, they did not define the functional or ultrastructural defects in their PCD group and, atypically, seven of the 10 patients reported to have PCD had normal CBF, calling into question their diagnosis. The two PCD patients with the common phenotype of static or extremely slow cilia showed no change in CBF following treatment with l-arginine [89].

Another reason for augmenting nitric oxide is its antibacterial properties [27, 101, 102]. Increasing nasal nitric oxide levels potentially reduces nasopharyngeal carriage of pathogens, thereby reducing the risk of lower respiratory tract infection. There is case in the literature of a healthy volunteer showing that nasal application of NOS inhibitors both reduces nasal NO and leads to sinus infection [96, 103].

Nitric oxide has a role in the dispersal of bacterial biofilms. P. aeruginosa is the best characterised bacteria to undergo the genetic adaptations from motile planktonic bacteria to a noncytotoxic, nonmotile, mucoid phenotype caused by overproduction of a surface polysaccharide known as alginate. Biofilm formation also occurs with Haemophilus influenzae and S. aureus, common pathogens in the PCD population [104106]. Bacteria embedded within biofilms can be 1,000-fold more resistant to antibiotic treatments [107]. They undergo coordinated dispersal events, in which the bacteria convert back to motile planktonic bacteria. Exposing in vitro P. aeruginosa biofilms to sodium nitroprusside, an nitric oxide donor, has been shown to induce biofilm dispersal, making it more susceptible to antimicrobial treatment [29]. Furthermore, recent studies have demonstrated that the slow release of nitric oxide from charged catheters inhibit Escherichia coli biofilm formation and also that sodium nitrite can kill P. aeruginosa, S. aureus and B. cepacia [27, 28].

While the evidence that augmenting nitric oxide can improve ciliary function in PCD is not compelling, the potential to promote host defence, by direct bactericidal properties and biofilm dispersal, merits further investigation. However, there is a potential risk that increasing nitric oxide levels may lead to increased nitrosative stress in what is already a pro-inflammatory environment.


While the association of low nitric oxide concentrations with PCD has been recognised for >15 yrs, the underlying mechanisms remain unclear. We have reviewed the data that demonstrate low levels of nasal nitric oxide in PCD to a degree that renders this a useful screening test. The limited studies to date suggest that biosynthesis of the molecule occurs, and there is little to suggest that increased breakdown or metabolism is responsible for the low levels. There is some direct and circumstantial data to suggest the reduced size of the paranasal sinuses caused by aplasia or opacification and the lack of patency of the osteomeatal complex might contribute. However, this is supported mainly by data from patients diagnosed with PCD who had normal levels of nasal nitric oxide and, given that the vast majority of PCD patients have extremely low nitric oxide levels, it does raise questions over the reliability of their diagnosis or the possibility of them having an usual phenotype of PCD. In order to clarify the underlying cause of the low levels of nitric oxide seen, it is essential to establish both whether the airway epithelium in PCD is able to biosynthesis normal levels of nitric oxide and the role played by abnormalities in the anatomy of the paranasal sinuses.

There has been speculation that nitric oxide augmentation may be beneficial in PCD and other diseases associated with low nitric oxide. It is unlikely that ciliary function will be normalised in common PCD phenotypes, although it has potential for treatment of patients with secondary dyskinesias. More plausible is the suggestion that nitric oxide augmentation will improve treatment of bacterial infections, particularly where biofilms are implicated. A number of small observational and in vitro studies have been conducted, but larger clinical trials are required before this can be considered a therapeutic option. The clinical implications and future directions of nitric oxide in PCD are presented in table 3.

View this table:
Table 3– Clinical implications and future directions


The Primary Ciliary Dyskinesia Diagnostic Service is commissioned by the Advisory Group for National Specialised Services (AGNSS).


  • Statement of Interest

    None declared.

  • Received October 11, 2011.
  • Accepted February 8, 2012.


View Abstract